Contrast MRI study for brain, spine, and body cancers
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests a new contrast agent called mangaciclanol for MRI scans of the central nervous system (brain and spine) or body areas like the chest, belly, pelvis, and muscles. You may join if you have known or suspected tumors that need an MRI with contrast, and you're healthy enough to have two contrast MRIs within a short time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) and can give informed consent.
- You have known or suspected tumors in the brain, spine, or certain body areas (head/neck, chest, belly, pelvis, or muscles) based on a recent scan (CT, PET, or MRI within the last year).
- You are scheduled for a contrast MRI and agree to have a second contrast MRI for the study.
- Your condition is stable (no sudden worsening in the last 2 days).
- You have adequate kidney function (eGFR test will be done to check).
- Women must not be pregnant and must use effective birth control for 30 days after the last dose; men must use effective birth control for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new contrast agent (a dye injected before an MRI) to see how well it works for people having brain or spinal cord scans. It aims to improve image quality so doctors can see lesions more clearly, which may help with diagnosis and treatment planning.
This trial tests whether two special MRI contrast medicines—gadolinium and ferumoxytol—can better diagnose problems in the brain or central nervous system. It may help doctors identify what’s causing symptoms or abnormal brain findings.
This study looks at whether getting the MRI contrast dye multiple times over 5 years affects body movement and thinking skills. It compares people who had the dye repeatedly with people who have little or no exposure, using brain MRI scans and regular mental and movement testing.
This trial compares two contrasting dyes (gadopiclenol and gadobutrol) used during pituitary MRI scans to see which one provides clearer images. It is for adults with known or suspected pituitary lesions that disrupt the blood-brain barrier.
This trial studies an MRI technique using a contrast dye (gadopetate/gadolinium) to better look at liver lesions that may be colon cancer spread. It may help doctors more accurately assess which liver tumors are present and guide next steps.
This trial uses a new type of MRI contrast dye (USPIO) to get clearer images of certain slow-growing brain tumors (vestibular schwannomas and low-grade gliomas). The goal is to see if this dye helps doctors better understand and treat these tumors.
Hear when a new Known or Highly Suspected Central Nervous System (CNS) Lesion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.